Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small molecule as complementary to its top-selling product, the blockbuster inflammatory bowel disorder drug Entyvio, and competitive against Bristol Myers Squibb's Sotyktu.
Builders Merchants News - Builders Merchants awards 20 Anniversary a huge success buildersmerchantsnews.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from buildersmerchantsnews.co.uk Daily Mail and Mail on Sunday newspapers.
Builders Merchants News - Builders Merchants Awards 20th anniversary a huge success buildersmerchantsnews.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from buildersmerchantsnews.co.uk Daily Mail and Mail on Sunday newspapers.